DEO vs HSY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Despite a strong Piotroski F-Score of 7/9 indicating operational stability, DEO is exhibiting severe fundamental decay and technical weakness. The stock is trading at a significant premium to both its Graham Number ($10.62) and Intrinsic Value ($49.15), while facing a catastrophic collapse in earnings growth (-62.3% YoY EPS). A dividend payout ratio of 95.64% is unsustainable given the negative revenue growth and crashing quarterly EPS, suggesting a high risk of a dividend cut. The technical trend is completely bearish (0/100), and long-term price performance is dismal (-49.1% over 5 years).
Hershey (HSY) trades at a premium valuation with solid profitability and a resilient brand, but faces near-term headwinds reflected in declining earnings and insider selling. Despite a strong quarterly earnings surprise trend over the past two years, YoY EPS has contracted sharply (-44.4%), and operating margins have compressed amid cost pressures. The stock is down 10.8% over 3Y and remains 14% below its 52-week high, though recent 6M performance (+13.9%) suggests stabilization. Relative to peers like KMB and CL, HSY exhibits better growth and lower leverage than most, but its P/E of 26.8x exceeds the sector average of 22.5x and forward P/E of 21.3x offers limited upside given earnings volatility.
Compare Another Pair
Related Comparisons
DEO vs HSY: Head-to-Head Comparison
This page compares Diageo plc (DEO) and The Hershey Company (HSY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.